ReviewJournal of nanobiotechnology2026
Advancement on localized targeting via intra-articular administration of lipid-based vesicular nanoparticles for osteoarthritis management.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a chronic degenerative arthritis with substantial global health and economic burden, especially intensified in recent year. The conventional therapeutics causes several systemic side effects via prolonged uses of oral or topical administration. To overcome the limitations of conventional therapeutics, lipid-based nanoparticles at localized site of administration represent a promising therapeutic approach for OA management, offering targeted drug delivery, enhanced bioavailability, and improved therapeutic outcomes. These nanosystems leverage their biocompatible lipid composition and nanoscale properties to overcome the significant challenges associated with conventional OA treatments. In this context, this comprehensive article summarizes the potential effectiveness of lipid-based delivery systems in OA management. The article initially summarizes the pathophysiology, role of inflammatory cytokines, matrix metalloproteinases, and lipid metabolism in OA management. The manuscript delves into the importance of lipid-based systems for therapeutic delivery and discusses various studies that summarize lipid-based delivery systems in preclinical settings for OA treatment, particularly focusing on the intra-articular administration of lipid-based nanoparticles in joint retention time, delayed lymphatic drainage, and electrostatic interactions with the extracellular matrix. The manuscript also enlisted a limited number of recent clinical trials and further assessed the safety profile of the localized administration of lipid-based delivery system in OA treatment. This manuscript is the first of its kind to compile and compare examples of lipid-based delivery systems against the existing literature focused on various delivery methods in OA management. This manuscript has been meticulously drafted, considering both the applications of first-generation lipid-based delivery systems in OA management and current innovative approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.